The FDA approved Corcept Therapeutics’ Lifyorli (relacorilant) for ovarian cancer months ahead of schedule in combination with nab-paclitaxel. The approval covers adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, across three cancer types described by the label. The clearance also underscores the continued use of early-approval lanes as Corcept positions Lifyorli after a prior FDA miss involving the same drug. Corcept also has another early readout pathway in the company’s strategy for expanding into additional tumor types while managing timelines to next-stage development.